Price and effectiveness analysis of the Indian version of Alpelisib

The situation of the Indian version of Alpelisib (Alpelisib) - Piqray has been a topic that has attracted more inquiries from breast cancer patients in recent years. According to overseas and market public information, the Apelvis currently circulating in the Indian market is the original version of the drug, which is also produced by the Swiss Novartis Pharmaceuticals (Novartis Ltd) and is not a generic drug. This is of great significance at the level of drug sources and ingredients, and also directly affects patients' trust in efficacy and safety. From the perspective of the nature of the drug, the Indian version is consistent with the Apelvis marketed in Europe or other regions in terms of active ingredients and mechanism of action. The differences are mainly reflected in the packaging form, instruction language, and specification settings.

In terms of price, due to differences in drug pricing systems, tax policies and exchange rates in different countries, the overall price of the Indian version of Apelvis is relatively more controllable. At present, common specifications such as150mg × 28 tablets, the price per box is about more than 7,000 yuan, and the actual cost will vary with exchange rate fluctuations and different purchasing channels. Compared with the market prices in Europe and the United States, this level is more accessible to some patients, so it has become a choice that many people are paying attention to.

In terms of efficacy, overseas data generally believe that as long as the original Apelvis is obtained through formal channels, its efficacy and safety are not essentially different from versions in other regions. The key influencing factors still lie in whether the patient has a PIK3CA mutation, whether the patient is combined with endocrine therapy, and the management of blood sugar and adverse reactions during medication. There is currently no authoritative data showing that the Indian version of Apelvis is less effective than other regional versions. At the same time, as of now, there is no Indian version of Apelvis generics officially on the market. If so-called "low-priced generic versions" appear on the market, patients should be extra cautious to avoid the risk of medication from unknown sources.

Taken together, under the premise of legal compliance, the Indian version of Apelvis reflects more on the price difference rather than the difference in efficacy, which is one of the core reasons why it has attracted attention.

Reference materials:https://www.piqray.com/